

- of the Human Genome (Vol. 4). Cooper DN (Ed.), Nature Publishing Group, London, 154-160 (2003).
14. Wada M, Uchiyama T, Kuwano M: Canalicular multispecific organic anion transporter, ABCG2. In: *Membrane Transport Diseases: Molecular Basis of Inherited Transport Defects*. Bröer S, Wagner CA (Eds), Kluwer Academic/Plenum Publishers, New York (2003) (In Press).
 15. Kanai Y, Endou H: Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. *J. Toxicol. Sci.* 28, 1-17 (2003).
 16. Ishikawa T, Yoshikawa M: ABC transporters: a new approach to toxicogenomics. In: *Toxicogenomics*. Inoue T, Pennic WD (Eds), Springer, Tokyo, 109-114 (2003).
 17. Srujigelski EM, Sirotkin K, Ward M *et al.*: dbSNP: a database of single nucleotide polymorphisms. *Nucleic Acids Res.* 28, 352-355 (2000).
 18. The International SNP Map Working Group: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. *Nature* 409, 928-933 (2001).
 19. Gushima, H: Japanese industry takes steps toward genomics-based medicine. *Global Outsourcing Rev.* 3, 30-37 (2001).
 20. Tsuji A: Transporter-mediated drug interactions. *Drug Metabol. Pharmacokin.* 17, 253-274 (2002).
 21. Liang R, Fei YJ, Prasad PD *et al.*: Human intestinal H⁺/peptide cotransporter. Cloning, functional expression, and chromosomal localization. *J. Biol. Chem.* 270, 6456-6463 (1995).
 22. Tamai I, Yabuuchi H, Nezu J *et al.*: Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. *FEBS Lett.* 419, 107-111 (1997).
 23. Yabuuchi H, Tamai I, Nezu J *et al.*: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. *J. Pharmacol. Exp. Ther.* 289, 768-773 (1999).
 24. Tamai I, Nakanishi T, Kobayashi D *et al.*: Involvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations. *Mol. Pharmacol.* (2004) (In Press).
 25. Hagenbuch B, Meier PJ: The superfamily of organic anion transporting polypeptides. *Biochim. Biophys. Acta* 1609, 1-18 (2003).
 26. Tamai I, Nezu J, Uchino H *et al.*: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. *Biochem. Biophys. Res. Commun.* 273, 251-260 (2000).
 27. Saito S, Iida A, Sekine A *et al.*: Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. *J. Hum. Genet.* 47, 576-584 (2002).
Catalog of SNPs of six human genes, including those coding for PEPT1, OCTN1 and OCTN2 in the Japanese population.
 28. Iida A, Saito S, Sekine A *et al.*: Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins. *J. Hum. Genet.* 46, 668-683 (2001).
Catalog of SNPs in genes, including those encoding OAT1 and OATP-C in the Japanese population.
 29. Nezu J, Tamai I, Oku A *et al.*: Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. *Nat. Genet.* 21, 91-94 (1999).
 30. Ohashi R, Tamai I, Nezu J *et al.*: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. *Mol. Pharmacol.* 59, 358-366 (2001).
 31. Ohashi R, Tamai I, Inano A *et al.*: Studies on functional sites of organic cation/carnitine transporter OCTN2 (SLC22A5) using a Ser467Cys mutant protein. *J. Pharmacol. Exp. Ther.* 302, 1286-1294 (2002).
 32. Nozawa T, Nakajima M, Tamai I *et al.*: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. *J. Pharmacol. Exp. Ther.* 302, 804-813 (2002).
•• Includes detailed data and allele frequency.
 33. Tirona RG, Leake BF, Merino G *et al.*: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. *J. Biol. Chem.* 276, 35669-35675 (2001).
 34. Nishizato Y, Ieiri I, Suzuki H *et al.*: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. *Clin. Pharmacol. Ther.* 73, 554-565 (2003).
 35. Gorboulev V, Ulzheimer J, Alkhoundova A *et al.*: Cloning and characterization of two human polyspecific organic cation transporters. *DNA Cell Biol.* 16, 871-881 (1997).
 36. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. *Mol. Pharmacol.* 51, 913-921 (1997).
 37. Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. *Nature* 372, 549-552 (1994).
 38. Jonker JW, Wagenaar E, Mol CA *et al.*: Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (*Oat1* [*Slc22a1*]) gene. *Mol. Cell Biol.* 21, 5471-5477 (2001).
 39. Wang D-S, Jonker JW, Kato Y, Kusuhara H, Shinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. *J. Pharmacol. Exp. Ther.* 302, 510-515 (2002).
 40. Kerb R, Brinkmann U, Chatskaia N *et al.*: Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. *Pharmacogenetics* 12, 591-595 (2002).
 41. Shu Y, Leabman MK, Feng B *et al.*: Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. *Proc. Natl. Acad. Sci. USA* 100, 5902-5907 (2003).
 42. Hirakawa M, Tanaka T, Hashimoto Y, Kuroda M, Takagi T, Nakamura Y: JSNP: a database of common gene variations in the Japanese population. *Nucleic Acids Res.* 30, 158-162 (2002).
 43. Sakata T, Anzai N, Shin HJ *et al.*: Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. *Biochem. Biophys. Res. Commun.* (2004) (In Press).
 44. Burckhardt G, Wolff NA: Structure of renal organic anion and cation transporters. *Am. J. Physiol. Renal Physiol.* 278, F853-F866 (2000).
 45. Dresser MJ, Gray AT, Giacomini KM: Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). *J. Pharmacol. Exp. Ther.* 292, 1146-1152 (2000).
 46. Takeuchi A, Motohashi H, Okuda M, Inui K: Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1. *Drug Metabol. Pharmacokin.* 18, 409-412 (2003).

47. Grantham R: Amino acid difference formula to help explain protein evolution. *Science* 185, 862-864 (1974).
48. Henikoff S, Henikoff JG: Amino acid substitution matrices from protein blocks. *Proc. Natl. Acad. Sci. USA* 89, 10915-10919 (1992).
49. Wang D-S, Jonker JW, Kato Y, Kusuhara H, Shinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. *J. Pharmacol. Exp. Ther.* 302, 510-515 (2002).
50. Klein I, Sarkadi B, Váradi A: An inventory of the human ABC proteins. *Biochim. Biophys. Acta* 1461, 237-262 (1999).
51. Dean M, Rzhetsky A, Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. *Genome Res.* 11, 1156-1166 (2001).
52. Higgins CF: ABC transporters: from microorganisms to man. *Ann. Rev. Cell Biol.* 8, 67-113 (1992).
53. Ling V: Multidrug resistance: molecular mechanisms and clinical relevance. *Cancer Chemother. Pharmacol.* 40, S3-S8 (1997).
54. Ambudkar SV, Dey S, Hryciyna CA *et al.*: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Ann. Rev. Pharmacol. Toxicol.* 39, 361-398 (1999).
55. Schinkel AH, Smit JJ, van Tellingen O *et al.*: Disruption of the mouse *mdr1a* P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. *Cell* 77, 491-502 (1994).
- The first report on *Mdr1a*-knockout mice, providing evidence that *Abcb1* plays a critical role in the blood-brain barrier.
56. Rao US: Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. *J. Biol. Chem.* 270, 6686-6690 (1995).
57. Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. *Pharmacogenomics* 2, 51-64 (2001).
58. Sparreboom A, Danesi R, Ando Y *et al.*: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. *Drug Resistance Update* 6, 71-84 (2003).
59. Saito S, Iida A, Sekine A *et al.*: Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese populations. *J. Hum. Genet.* 47, 38-50 (2002).
60. Schwab M, Eichelbaum M, Fromm MF: Genetic polymorphisms of the human MDR1 drug transporter. *Ann. Rev. Pharmacol. Toxicol.* 43, 285-307 (2003).
61. Evans WE, McLeod HL: Pharmacogenomics – drug disposition, drug targets, and side effects. *N. Engl. J. Med.* 348, 538-549 (2003).
62. Weinshilboum R: Inheritance and drug response. *N. Engl. J. Med.* 348, 529-537 (2003).
63. Ito M, Saito Y, Komamura K *et al.*: Twelve novel single nucleotide polymorphisms in ABCB1/MDR1 among Japanese patients with ventricular tachycardia who were administered amiodarone. *Drug Metab. Pharmacokin.* 17, 566-571 (2002).
64. Anglicheau D, Versnyft C, Laurent-Puig P *et al.*: Association of multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirement in renal transplant recipients. *J. Am. Soc. Nephrol.* 14, 1889-1896 (2003).
65. Kafka A, Sauer G, Jaeger C *et al.*: Polymorphism C3435T of the *MDR-1* gene predicts response to preoperative chemotherapy in locally advanced breast cancer. *Int. J. Oncol.* 22, 1117-1121 (2003).
66. Brummé ZL, Dong WW, Chan KL *et al.*: Influence of polymorphisms within the *CX3CR1* and *MDR-1* genes on initial antiretroviral therapy response. *AIDS* 17, 201-208 (2003).
67. Macphée IA, Fredericks S, Tai T *et al.*: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. *Transplantation* 74, 1486-1489 (2002).
68. Johne A, Kopke K, Gerloff T *et al.*: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein *MDR1* gene. *Clin. Pharmacol. Ther.* 72, 584-594 (2002).
69. Siegrund W, Ludwig K, Giessmann T *et al.*: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. *Clin. Pharmacol. Ther.* 72, 572-583 (2002).
70. Kim RB: MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. *Pharmacogenetics* 12, 425-427 (2002).
71. Roberts RL, Joyce PR, Mulder RT *et al.*: A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. *Pharmacogenomics J.* 2, 191-196 (2002).
72. Calado RT, Falcao RP, Garcia AB *et al.*: Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34⁺ hematopoietic stem cells. *Haematologica* 87, 564-568 (2002).
73. Hoffmeyer S, Burk O, Von Richter O *et al.*: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity *in vivo*. *Proc. Natl. Acad. Sci. USA* 97, 3473-3478 (2000).
- The first report presenting that the C3435T polymorphism affects the expression of ABCB1 and the pharmacokinetics of digoxin. Expression of ABCB1 was significantly lower in patients with the T allele.
74. Balram C, Sharma A, Sivathasan C *et al.*: Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. *Br. J. Clin. Pharmacol.* 56, 78-83 (2003).
75. Tang K, Ngoi SM, Gwee PC *et al.*: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. *Pharmacogenetics* 12, 437-450 (2002).
76. Illmer T, Schuler US, Thiede C *et al.*: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. *Cancer Res.* 62, 4955-4962 (2002).
- Expression of ABCB1 was significantly lower in patients with CC alleles.
77. Drescher S, Scheffeler E, Hitzl M *et al.*: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. *Br. J. Clin. Pharmacol.* 53, 526-534 (2002).
78. Hitzl M, Drescher S, Van der Kuip H *et al.*: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56⁺ natural killer cells. *Pharmacogenetics* 11, 293-298 (2001).
79. Fellay J, Marzolini C, Meaden ER *et al.*: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetic study. *Lancet* 359, 30-36 (2002).
- Expression of ABCB1 was significantly lower in patients with the T allele.
80. Nakamura T, Sakaeda T, Horinouchi M *et al.*: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression

- level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. *Clin. Pharmacol. Ther.* 71, 297-303 (2002).
- Expression of ABCB1 was significantly lower in patients with the T allele.
81. Moriya Y, Nakamura T, Horinouchi M *et al.*: Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNAs expression levels in duodenal enterocytes of healthy Japanese subjects. *Biol. Pharm. Bull.* 25, 1356-1359 (2002).
 82. Van der Heiden LP, Van der Heuvel MM, Wiemer E *et al.*: MDR-1 C3435T gene polymorphisms does not correlate with P-glycoprotein expression and function in acute myeloid leukemia. *Clin. Pharmacol. Ther.* 73, 58 (Abstract) (2003).
 - No significant difference in ABCB1 expression levels between C and T alleles.
 83. Desai DG, Maruyama N, Lantz M *et al.*: The functional change of P-glycoprotein on lymphocytes under induction condition as a function of MDR1 polymorphisms. *Clin. Pharmacol. Ther.* 37, 13 (Abstract) (2003).
 - No significant difference in ABCB1 expression levels between C and T alleles.
 84. Von Ahnen N, Richter M, Grupp C *et al.*: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. *Clin. Chem.* 47, 1048-1052 (2001).
 85. Min DI, Elingrod VL: C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. *Ther. Drug Monit.* 24, 400-404 (2002).
 86. Chowbay B, Kumaraswamy S, Cheng YB *et al.*: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. *Pharmacogenetics* 13, 89-95 (2003).
 87. Van Schaik R, Hesselink DA, Van der Heiden IP *et al.*: Tacrolimus, but not cyclosporin, drug levels are correlated with CYP3A5*3 and CYP3A4*1B genotype no correlation with the MDR-1 C3435T polymorphism. *Clin. Pharmacol. Ther.* 73, 56 (Abstract) (2003).
 88. Putnam W, Desai DG, Huang Y *et al.*: The effect of induction condition and MDR1 genotypes on didoxacillin pharmacokinetics. *Clin. Pharmacol. Ther.* 73, 57 (Abstract) (2003).
 89. Becquemont L, Verstuyft C, Kerb R *et al.*: Effect of grapefruit juice on digoxin pharmacokinetics in humans. *Clin. Pharmacol. Ther.* 70, 311-316 (2001).
 90. Sakaeda T, Nakamura T, Horinouchi M *et al.*: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. *Pharm. Res.* 18, 1400-1404 (2001).
 91. Gerloff T, Schaefer M, John A *et al.*: MDR1 genotypes do not influence the absorption of a single oral dose of 1mg digoxin in healthy white males. *Br. J. Pharmacol.* 54, 610-616 (2002).
 92. Kurata Y, Ieiri I, Kimura M *et al.*: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. *Clin. Pharmacol. Ther.* 72, 209-219 (2002).
 93. Verstuyft C, Strabach S, El Morabet H *et al.*: Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. *Clin. Pharmacol. Ther.* 73, 51-60 (2003).
 94. Goh BC, Lee SC, Wang LZ *et al.*: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. *J. Clin. Oncol.* 20, 3683-3690 (2002).
 95. Goto M, Masuda S, Saito H *et al.*: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. *Pharmacogenetics* 12, 451-457 (2002).
 96. Yamauchi A, Ieiri I, Kataoka Y *et al.*: Neurotoxicity induced by tacrolimus after liver transplantation: relation to polymorphisms of the ABCB1 (MDR1) gene. *Transplantation* 74, 571-572 (2002).
 97. Mathijssen RH, Loos WJ, Verweij J *et al.*: Pharmacokinetic and pharmacogenetic analysis of irinotecan (CPT-11) in combination with R115777. *Eur. J. Cancer* 38, S44 (Abstract) (2002).
 98. Kimchi-Sarfary C, Griber JJ, Gottesman MM: Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. *Mol. Pharmacol.* 62, 1-6 (2002).
 99. Mickley LA, Lee JS, Weng Z *et al.*: Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. *Blood* 91, 1749-1756 (1998).
 100. Kim RB, Leake BF, Choo EF *et al.*: Identification of functionally variant MDR1 alleles among European Americans and African Americans. *Clin. Pharmacol. Ther.* 70, 189-199 (2001).
 101. Carter SG, Karl DW: Inorganic phosphate assay with malachite green: an improvement and evaluation. *J. Biochem. Biophys. Methods* 7, 7-13 (1982).
 102. Sarkadi B, Price EM, Boucher RC *et al.*: Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. *J. Biol. Chem.* 267, 4854-4858 (1992).
 103. Borst P, Evers R, Koel M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. *J. Natl. Cancer Inst.* 92, 1295-1302 (2000).
 104. Ishikawa T, Kuo MT, Furuta K, Suzuki M: The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design. *Clin. Chem. Lab. Med.* 38, 893-897 (2000).
 105. König J, Nies AT, Cui Y, Keppler D: MRP2, the apical export pump for anionic conjugates. In: *ABC Proteins: from Bacteria to Man*. Holland IB, Cole SPC, Kuchler K, Higgins CF (Eds), Academic Press, Amsterdam, 423-443 (2003).
 106. Taniguchi K, Wada M, Kohno K *et al.*: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. *Cancer Res.* 56, 4124-4129 (1996).
 107. Buchler M, König J, Brom M *et al.*: cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. *J. Biol. Chem.* 271, 15091-15098 (1996).
 108. Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu N, Sugiyama Y: Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR rats. *Am. J. Physiol.* 35, G16-G22 (1997).
 109. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL: Congenital jaundice in rats with a mutation in a multidrug resistance associated protein gene. *Science* 271, 1126-1128 (1996).
 110. Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T: Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/CGS-X pump. *Biochem. Biophys. Res. Commun.* 247, 859-863 (1998).
 111. Lee DW, Deeley RG, Cole SP: Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport

- with reduced glutathione. *Cancer Res.* 58, 5130-5136 (1998).
112. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. *Cancer Res.* 56, 988-994 (1996).
 113. Ishikawa T: The ATP-dependent glutathione S-conjugate export pump. *Trends Biochem. Sci.* 17, 463-468 (1992).
 114. Bakos E, Evers R, Sinkule JA, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. *Mol. Pharmacol.* 57, 760-768 (2000).
 115. Loe DW, Almquist KC, Deeley RG, Cole SPC: Multidrug resistance protein (MRP)-mediated transport of leukotriene C₄ and chemotherapeutic agents in membrane vesicles: demonstration of glutathione-dependent vincristine transport. *J. Biol. Chem.* 271, 9675-9682 (1996).
 116. Loe DW, Almquist KC, Cole SPC, Deeley RG: ATP-dependent 17 β -estradiol 17-(β -D-glucuronide) transport by multidrug resistance protein: inhibition by cholestatic steroids. *J. Biol. Chem.* 271, 9683-9689 (1996).
 117. Loe DW, Stewart RK, Massey TE, Deeley RG, Cole SPC: ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the MRP gene. *Mol. Pharmacol.* 51, 1034-1041 (1997).
 118. Ishikawa T, Müller M, Klünemann C *et al.*: ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. *J. Biol. Chem.* 265, 19279-19286 (1990).
 119. Evers R, Cnubben NH, Wijnhouds J, van Deemter L, van Bladeren PJ, Borst P: Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. *FEBS Lett.* 419, 112-116 (1997).
 120. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. *Biochim. Biophys. Acta* 1326, 12-22 (1997).
 121. Hooijberg JH, Broxterman HJ, Heijn M, Fles DL, Lankelma J, Pinedo HM: Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. *FEBS Lett.* 413, 344-348 (1997).
 122. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, Keppler D: ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. *Biochem. J.* 327, 305-310 (1997).
 123. Toh S, Wada M, Uchiyama T *et al.*: Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. *Am. J. Hum. Genet.* 64, 739-746 (1999).
 124. Frank M, Doss M, de Carvalho DG: Diagnostic and pathogenetic implications of urinary coproporphyrin excretion in the Dubin-Johnson syndrome. *Hepatology* 37, 147-151 (1990).
 125. Takino T, Takahashi T, Okuno T: Clinical study of the constitutional hyperbilirubinemia in Japan. A nationwide survey between 1970 and 1974. *Jpn. J. Gastroenterol.* 74, 1518-1528 (1977).
 126. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. *Pharmacogenetics* 11, 175-184 (2001).
 127. Saito S, Iida A, Sekine A *et al.*: Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). *J. Hum. Genet.* 47, 147-171 (2002).
 128. Suzuki H, Sugiyama Y: Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. *Adv. Drug Deliver. Rev.* 54, 1311-1331 (2002).
 129. Kartenbeck J, Leuschner U, Mayer R, Keppler D: Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. *Hepatology* 23, 1061-1066 (1996).
 130. Keppler D, Kartenbeck J: The canalicular conjugate export pump encoded by the *mrp/cmoat* gene. *Prog. Liver Dis.* 14, 55-67 (1996).
 131. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, Ter Borg F, Scheper RJ: Mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. *Hepatology* 25, 1539-1542 (1997).
 132. Tsujii H, Konig J, Rost D, Stockel B, Leuschner U, Keppler D: Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. *Gastroenterology* 117, 653-660 (1999).
 133. Wada M, Toh S, Taniguchi K *et al.*: Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. *Hum. Mol. Genet.* 7, 203-207 (1998).
 134. Tate G, Li M, Suzuki T, Mitsuya T: A new mutation of the ATP-binding cassette, subfamily C, member 2 (ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. *Genes Genet. Syst.* 77, 117-121 (2002).
 135. Keitel V, Kartenbeck J, Nies AT, Spring H, Brom M, Keppler D: Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. *Hepatology* 32, 1317-1328 (2000).
 136. Mor-Cohen R, Zivelin A, Rosenberg N, Shani M, Muallem S, Seligsohn U: Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. *J. Biol. Chem.* 276, 36923-36930 (2001).
 137. Hashimoto K, Uchiyama T, Konno T *et al.*: Trafficking-defect and functional-defect by mutations of the ATP-binding domains in multidrug resistance protein 2 in patients with Dubin-Johnson syndrome. *Hepatology* 36, 1236-1245 (2002).
 138. Schwartz AL, Ciechanover A: The ubiquitin-proteasome pathway and pathogenesis of human diseases. *Ann. Rev. Med.* 50, 57-74 (1999).
 139. Senior AE, al-Shawi MK, Urbatsch IL: The catalytic cycle of P-glycoprotein. *FEBS Lett.* 377, 285-289 (1995).
 140. Urbatsch IL, Sankaran B, Weber J, Senior AE: P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. *J. Biol. Chem.* 270, 19383-19390 (1995).
 141. Gao M, Cui HR, Loe DW *et al.*: Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. *J. Biol. Chem.* 275, 13098-13108 (2000).
 142. Nagata K, Nishitani M, Matsuo M, Kioka N, Amachi T, Ueda K: Nonequivalent nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance protein MRP1. *J. Biol. Chem.* 275, 17626-17630 (2000).
 143. Hung LW, Wang IX, Nikaido K, Liu PQ, Ames GF, Kim SH: Crystal structure of the ATP-binding subunit of an ABC transporter. *Nature* 396, 703-707 (1998).

144. Dork T, Mekus F, Schmidt K *et al.*: Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. *Hum. Genet.* 94, 533-542 (1994).
145. Diederichs K, Diez J, Greller G *et al.*: Crystal structure of MalK, the ATPase subunit of the trehalose/maltose ABC transporter of the archaeon *Thermococcus litoralis*. *EMBO J.* 19, 5951-5961 (2000).
146. Kajihara S, Hisatomi A, Mizuta T *et al.*: A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome. *Biochem. Biophys. Res. Commun.* 253, 454-457 (1998).
147. Doyle LA, Yang W, Abruzzo LV *et al.*: A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc. Natl. Acad. Sci. USA* 95, 15665-15670 (1998).
148. Allikmets R, Schriml LM, Hutchinson A *et al.*: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. *Cancer Res.* 58, 5337-5339 (1998).
149. Miyake K, Mickley L, Litman T *et al.*: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. *Cancer Res.* 59, 8-13 (1999).
150. Schmitz G, Langmann T, Heimerl S: Role of ABCG1 and other ABCG family members in lipid metabolism. *J. Lipid Res.* 42, 1513-1520 (2001).
151. Kage K, Tsukahara S, Sugiyama T *et al.*: Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. *Int. J. Cancer* 97, 626-630 (2002).
152. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD: Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. *Biochim. Biophys. Acta* 1520, 234-241. (2001).
153. Maliepaard M, Scheffer GL, Faneyte IF *et al.*: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. *Cancer Res.* 61, 3458-3464 (2001).
154. Zhou S, Schuetz JD, Bunting KD *et al.*: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nat. Med.* 7, 1028-1034 (2001).
155. Jonker JW, Buitelaar M, Wagenaar E *et al.*: The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. *Proc. Natl. Acad. Sci. USA* 99, 15649-15654 (2002).
156. Maliepaard M, van Gastelen MA, de Jong LA *et al.*: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. *Cancer Res.* 59, 4559-4563 (1999).
157. Ross DD, Yang W, Abruzzo LV *et al.*: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. *J. Natl. Cancer Inst.* 91, 429-433 (1999).
158. Brangi M, Litman T, Ciotti M *et al.*: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. *Cancer Res.* 59, 5938-5946 (1999).
159. Litman T, Brangi M, Hudson E *et al.*: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). *J. Cell Sci.* 113, 2011-2021 (2000).
160. Nakagawa R, Hara Y, Arakawa H, Nishimura S, Komatani H: ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport. *Biochem. Biophys. Res. Commun.* 299, 669-675 (2002).
161. Ross DD: Novel mechanisms of drug resistance in leukemia. *Leukemia* 14, 467-473 (2000).
162. Van der Kolk DM, Vellenga E, Scheffer GL *et al.*: Expression and activity of breast cancer resistance protein (BCRP) in *de novo* and relapsed acute myeloid leukemia. *Blood* 99, 3763-3770 (2002).
163. Kawabata S, Oka M, Shiozawa K *et al.*: Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. *Biochem. Biophys. Res. Commun.* 280, 1216-1223 (2001).
164. Nakatomi K, Yoshikawa M, Oka M *et al.*: Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. *Biochem. Biophys. Res. Commun.* 288, 827-832 (2001).
165. Honjo Y, Hrycyna CA, Yan Q-W *et al.*: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. *Cancer Res.* 61, 6635-6639 (2001).
166. Komatani H, Kotani H, Hara Y *et al.*: Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. *Cancer Res.* 61, 2827-2832 (2001).
167. Mitomo H, Kato R, Ito A *et al.*: A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of Arg-482 in methotrexate transport. *Biochem. J.* 373, 767-774 (2003).
168. Chen A-S, Robey RW, Belinsky MG *et al.*: Transport of methotrexate, methotrexate polyglutamates, and 17 β -estradiol 17-(β -D-glucuronide) by ABCG2: effect of acquired mutations at R482 on methotrexate transport. *Cancer Res.* 63, 4048-4054 (2003).
169. Volk EL, Schneider E: Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. *Cancer Res.* 63, 5538-5543 (2003).
170. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E: Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. *Cancer Res.* 62, 5035-5040 (2002).
171. Honjo Y, Morisaki K, Huff LM *et al.*: Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). *Cancer Biol. Ther.* 1, 696-702 (2002).
172. Iida A, Saito S, Sekine A *et al.*: Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. *J. Hum. Genet.* 47, 285-310 (2002).
173. Imai Y, Nakane M, Kage K *et al.*: C421A polymorphism in human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. *Mol. Cancer Ther.* 1, 611-616 (2002).
174. Itoda M, Saito Y, Shirao K *et al.*: Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotecan. *Drug. Metab. Pharmacokin.* 18, 212-217 (2003).
175. Chowbay B, Kibat C, Zhou Q, Li HH, Lee EJD: Genetic polymorphism and allelic association in the ABCG2 in three distinct Asian population. *Pharmacogenetics* (2003) (In Press).
176. Zamber CP, Lamba JK, Yasuda K *et al.*: Natural allelic variations of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human

- intestine. *Pharmacogenetics* 13, 19-28 (2003).
177. Bäckström G, Taipalensuu J, Melhus H *et al.*: Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. *Eur. J. Pharm. Sci.* 18, 359-364 (2003).
 178. Ishikawa T, Kasamitsu S, Hagiwara Y *et al.*: Expression and functional characterization of human ABC transporter ABCG2 variants in insect cells. *Drug Metabol. Pharmacokin.* 18, 194-202 (2003).
 179. Ishikawa T: ATP/Mg²⁺-dependent cardiac transport system for glutathione S-conjugates: a study using heart sarcolemma vesicles. *J. Biol. Chem.* 264, 17343-17348 (1989).
 - The original method for the measurement of membrane vesicle transport.
 180. Yoshikawa M, Ikegami Y, Sano K *et al.*: Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. *J. Exp. Ther. Oncol.* (2004) (In Press).
 181. Fromm MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. *Adv. Drug. Deliv. Rev.* 54, 1295-1310 (2002).
 182. Siddiqui A, Kerb R, Weale ME *et al.*: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. *N. Engl. J. Med.* 348, 1442-1448 (2003).
 183. Morita N, Yasumori T, Nakayama K: Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. *Biochem. Pharmacol.* 65, 1843-1852 (2003).
 184. Efferth T, Sauerbrey A, Steinbach D *et al.*: Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. *Int. J. Oncol.* 23, 509-517 (2003).
 185. Yates CR, Zhang W, Song P *et al.*: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. *J. Clin. Pharmacol.* 43, 555-564 (2003).
 186. Sakaeda T, Nakamura T, Okumura K: Pharmacogenomics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. *Pharmacogenomics* 4, 397-410 (2003).
 187. Kroetz DL, Pauli-Magnus C, Hodges LM *et al.*: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter). *Pharmacogenetics* 13, 481-494 (2003).
 188. Westphal K, Weinbrenner A, Zschiesche M *et al.*: Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. *Clin. Pharmacol. Ther.* 68, 345-355 (2000).
 189. Dürr D, Süeger B, Kullak-Ublick GA *et al.*: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. *Clin. Pharmacol. Ther.* 68, 598-604 (2000).
 190. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K: Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. *Clin. Pharmacol. Ther.* 68, 98-103 (2000).
 191. Hashida T, Masuda S, Uemoto S *et al.*: Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. *Clin. Pharmacol. Ther.* 69, 308-316 (2001).
 192. Chawla A, Repa JJ, Evans RM, Mangoldorf DJ: Nuclear receptors and lipid physiology: opening the X-files. *Science* 294, 1866-1870 (2001).

Websites

201. <http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html>
Nomenclature for human ABC-transporter genes website.
202. [http://www.ncbi.nlm.nih.gov/omim/Carnitine deficiency, systemic primary](http://www.ncbi.nlm.nih.gov/omim/Carnitine%20deficiency,%20systemic%20primary). Online Mendelian Inheritance in Man, OMIM™, Johns Hopkins University, Baltimore, MD, USA. MIM number:212140, last edited 9/19/2002.
203. <http://snp.ims.u-tokyo.ac.jp/>
A database of Japanese single nucleotide polymorphisms.
204. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=snp>
SNP database of NCBI.

Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine

Kyoko Fujiwara, Masako Ochiai, Tsutomu Ohta¹, Misao Ohki¹, Hiroyuki Aburatani², Minako Nagao, Takashi Sugimura and Hitoshi Nakagama³

Biochemistry Division and ¹Medical Genetics Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan and ²Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan

³To whom correspondence should be addressed. Tel: +81 3 3547 5239; Fax: +81 3 3542-2530; Email: hnakagam@gan2.res.ncc.go.jp

Colon cancers develop after accumulation of multiple genetic and epigenetic alterations in colon epithelial cells. To shed light on global changes in gene expression of colon cancers and to gain further insight into the molecular mechanisms underlying colon carcinogenesis, we have conducted a comprehensive microarray analysis of mRNA using a rat colon cancer model with the food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP). Of 8749 genes or ESTs on a high density oligonucleotide microarray, 27 and 46 were over- and under-expressed, respectively, by ≥ 3 -fold in colon cancers in common in two rat strains with distinct susceptibility to PhIP carcinogenesis. For example, genes involved in inflammation and matrix proteases and a cell cycle regulator gene, *cyclin D2*, were highly expressed in colon cancers. In contrast, genes encoding structural proteins, muscle-related proteins, matrix-composing and mucin-like proteins were underexpressed. Interestingly, a subset of genes whose expression is characteristic of Paneth cells, i.e. the *defensins* and *matrilysin*, were highly overexpressed in colon cancers. The presence of *defensin 3* and *defensin 5* transcripts in cancer cells could also be confirmed by *in situ* mRNA hybridization. Furthermore, Alcian blue/periodic acid Schiff base (AB-PAS) staining and immunohistochemical analysis with an anti-lysozyme antibody demonstrated Paneth cells in the cancer tissues. AB-PAS-positive cells were also observed in high grade dysplastic aberrant crypt foci, which are considered to be preneoplastic lesions of the colon. Our results suggest that Paneth cell differentiation in colon epithelial cells could be an early morphological change in cryptic cells during colon carcinogenesis.

Introduction

The development of colon cancers comprises multiple steps requiring the accumulation of genetic and epigenetic alterations in colon epithelial cells, and these changes further affect

Abbreviations: AB-PAS, Alcian blue/periodic acid Schiff base; ACF, aberrant crypt foci; DIG, digoxigenin; APC, adenomatous polyposis coli; EST, expressed sequence tagged; H&E, hematoxylin and eosin; PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine.

expression of a variety of downstream genes and may cause considerable changes in gene expression profiles in cancer cells as a consequence. Inactivation of the *adenomatous polyposis coli* (APC) gene, β -catenin, K-RAS, SMAD2, SMAD4, p53 and mismatch repair genes by genetic alterations, for example, play key roles (1,2). Furthermore, alterations of gene expression profiles by perturbation of CpG island methylation in promoter regions and/or the histone acetylation/deacetylation status of chromatin also have a substantial impact on colon carcinogenesis (2).

Oral administration of 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine (PhIP), one of the most abundant heterocyclic amines produced while cooking meat and fish (3,4), induces aberrant crypt foci (ACF) (5,6), putative preneoplastic lesions of the colon (7,8), in experimental animals within a short period and colon adenomas and adenocarcinomas after 1 or 2 years in rats, preferentially in males (9). A number of studies have revealed that PhIP-induced rat colon cancers resemble human neoplasms with regard to observed histological features and genetic alterations (10–14). There are several advantages with the use of animal cancer models to dissect the molecular basis of colon carcinogenesis. For example, inbred experimental animals share a common genetic background within the strain and, furthermore, carcinogenesis experiments using these animals can be carried out under well-controlled conditions. Genetic and/or epigenetic alterations in colon cancers induced in experimental animals are therefore expected to be more uniform compared with those in humans with diverse genetic backgrounds. Colon cancers induced by PhIP indeed demonstrate β -catenin accumulation in both cytoplasm and nucleus (13) and β -catenin mutations are observed at codons 32, 34, 36 or 38 in exon 2, the majority being G \rightarrow T transversions (12,13). In the *Apc* gene, 5'-GGGA-3' sites in exons 14 and 15 and a 5'-agGGGGG-3' site at the junction of intron 10 and exon 11 are mutation hot-spots (10,13). Using a model system, we have recently revealed sequential progression from dysplastic ACF to colon cancer (14,15). Although the PhIP-induced rat colon cancer model has provided cancer researchers with a powerful tool for dissecting molecular events involved in the formation of colon cancers with relevance to human colon carcinogenesis, extensive studies aimed at the elucidation of early genetic events in colon cancer development have hitherto not been conducted.

In the present study we therefore performed a global gene expression analysis of rat colon cancers induced by PhIP using high density oligonucleotide microarrays (GeneChip; Affymetrix, Santa Clara, CA). To eliminate detection of strain-specific changes, but rather to detect specific gene expression profiles essential for colon cancer development, two rat strains, F344 and ACI, were subjected to analysis, the former being the more susceptible to PhIP-induced colon carcinogenesis. A considerable number of genes were found to be differentially expressed in colon cancers compared with normal counterpart epithelium, including examples characteristic of Paneth cells. Global

changes in gene expression profiles are also discussed in comparison with those reported in human colon cancers. Another focus is on the appearance of Paneth cells in ACF, especially in dysplastic ones, and its biological significance.

Materials and methods

Animals and diets

PhIP was purchased from the Nard Institute (Osaka, Japan) in the form of PhIP-HCl and added to AIN-93G basal diet (7% w/w soybean oil; Dyets, Bethlehem, PA) at a concentration of 400 p.p.m. A high fat diet (AIN-93G basal diet supplemented with 23% w/w hydrogenated vegetable oil) was also purchased from Dyets. Five-week-old male F344 and ACI strain rats were purchased from CLEA Japan (Tokyo, Japan) and housed 3 per cage in an air-conditioned animal room with a 12 h light/dark cycle. Prior to the experiment, all the animals were acclimatized to the housing environment and the AIN-93G basal diet for 1 week.

Experimental protocol and tissue samples

Starting at the age of 6 weeks, rats were fed a diet containing PhIP following an intermittent PhIP feeding protocol (13). At experimental week 60 all animals were killed and colons were removed. When colon cancers with polypoid growth were detected by the naked eye, cancerous parts were resected with a razor blade, bisected and one half was embedded in O.C.T. compound (Tissue-Tek; Sakura Finetechnical Co., Tokyo, Japan), frozen and stored at -80°C until use for frozen section preparation and RNA extraction. The remaining halves were fixed in neutral 10% formalin overnight at 4°C and embedded in paraffin blocks according to standard procedures. Normal counterparts were collected from the surrounding normal parts of the colon and separately embedded in O.C.T. compound and samples were snap-frozen in liquid nitrogen and stored at -80°C until use for RNA extraction. In separate experiments using the intermittent PhIP feeding protocol, ACF were assayed at experimental weeks 18 and 25, after fixation of tissue in formalin and embedding in paraffin blocks as described above.

High density oligonucleotide microarray analysis

Twelve colon cancer tissues, six each from F344 and ACI rats, and 12 normal counterparts were collected by digging them out of frozen O.C.T. blocks using 18 gauge needles. Total RNA was extracted from ~ 1 mg of tissue with TRIZOL reagent (Invitrogen, Carlsbad, CA). Two of six colon cancer tissues from F344 rats, however, did not provide sufficient amounts of good quality RNA. The remaining four samples from F344 and six from ACI rats were subjected to the following experiments. cRNA was synthesized, labeled with biotin and hybridized to high density oligonucleotide microarrays, Rat Genome U34A (RG U34A; Affymetrix), as described previously. The average hybridization intensity for each array was scaled to 1000 to reliably compare multiple arrays. Prior to statistical analysis, genes were filtered according to the following criteria. For genes overexpressed in cancers, for example, they should have 'present (P)' or 'marginal (M)' calls in at least half of the colon cancer samples of the respective rat strains. For genes underexpressed in cancers, in contrast, they should have P or M calls at least in half of the normal counterpart samples. To assess statistical differences in gene expression between colon cancers and normal tissues, average signal intensity and standard variation were calculated for each group and GeneSpring 4.3

(Silicon Genetics, Redwood City, CA) was employed for the Mann-Whitney *U*-test. The significant *P* value was set at 0.05. Then, genes which were differentially expressed between cancer and normal tissue at ≥ 3 -fold were selected and subjected to further analysis, including Venn diagrams, hierarchical clustering analysis, functional classification and comparison with expression profiles of human colon cancers. Permutation analysis was also carried out to assess the statistical significance of genes differentially expressed between the two rat strains.

Histological analysis

For hematoxylin and eosin (H&E) staining, paraffin sections were prepared at $3.5\ \mu\text{m}$ thickness following standard procedures. Histological evaluation of colonic lesions was performed as described previously (13). For Alcian blue (pH 2.5)/periodic acid Schiff base (AB-PAS) staining to evaluate the presence of Paneth cells, both frozen ($10\ \mu\text{m}$ thickness) and paraffin ($3.5\ \mu\text{m}$ thickness) sections were used. The staining was carried out according to conventional methods.

In situ mRNA hybridization for defensin genes

In situ mRNA hybridization was carried out as described previously (16,17) under contract by Genostaff (Tokyo, Japan) using frozen sections prepared at $10\ \mu\text{m}$ thickness. A 293 bp cDNA fragment of the rat neutrophil defensin 3 gene was amplified by PCR with primers 5'-CTCCCTGCATACGCCAAAG-3' (forward) and 5'-AACAGAGTCGGTAGATGCC-3' (reverse) and a 335 bp cDNA fragment of the defensin 5 gene with primers 5'-AACTGTCTCTCTTCTGCCC-3' (forward) and 5'-AACATCAGCATCGGTGGCC-3' (reverse). Amplified fragments were cloned into pCRII (Invitrogen) and digoxigenin (DIG)-labeled RNA probes were generated by an *in vitro* transcription method using DIG-labeling mix (Roche Molecular Biochemicals, Tokyo, Japan). Hybridized probes were detected by an IgG antibody against the DIG label and visualized with NBT/BCIP solution (Roche Molecular Biochemicals). Nuclear counterstaining was performed with Kernerchtrot Stain Sol (Muto Chemical, Tokyo, Japan).

Semi-quantitative RT-PCR

Extracted RNA was transcribed to cDNA using an oligo(dT)₁₂₋₁₈ primer and SuperScript™ II reverse transcriptase (Invitrogen) and the cDNAs produced were divided into aliquots in tubes and stored at -20°C until analyzed. Each aliquot of cDNA was subjected to semi-quantitative reverse transcription (RT)-PCR with the primer sequences listed in Table I. A set of semi-quantitative RT-PCR reactions for representative genes was carried out within 1 day to avoid the effects of degradation of cDNA templates. For reference, expression of the β -actin and glyceraldehyde 3-phosphate dehydrogenase (*G3PDH*) genes was also quantified for each sample. PCR amplification was carried out at 94°C for 30 s, 60°C for 30 s and 72°C for 1 min using Advantage Taq (Clontech, Palo Alto, CA) under the conditions recommended by the manufacturer. PCR cycles were set at 25 for β -actin and *G3PDH*, 35 for α -defensin NP4 and β -defensin 2 and 30 cycles for the other genes. PCR products were also analyzed by gel electrophoresis on a 2% agarose gel in $0.5\times$ TBE (89 mM Tris, 89 mM boric acid, 1.9 mM EDTA). The amounts of PCR products were quantified by analysis performed on a Macintosh iBook G3 computer using the public domain NIH Image program (developed at the US National Institutes of Health and available on the Internet by anonymous ftp from zippy.nimh.nih.gov. or on floppy disk from the National Technical Information Service, Springfield, VA, part no. PB95-500195GEI). PCR reactions for individual genes were

Table I. List of primers used for RT-PCR

Gene name	Forward primer	Reverse primer
Matrilysin	5'-TTCGCAAGGGGAGATCACG-3'	5'-AACAGAAGAGTGAACCCAGAC-3'
Mash2	5'-TTACCCATGCTGTCTAGTGC-3'	5'-AGTCTCCAGCAGTTCAAAGT-3'
Oct1A	5'-CCITCATCATCCTGGTCAAC-3'	5'-ATGAAGGGGGTGAAGATCC-3'
Carbonic anhydrase IV	5'-GGTAAACGAGGGCTCCAG-3'	5'-TGAGACCTGAACACCTGCC-3'
AA799832	5'-GCGATCATGCCTTGCTTAAC-3'	5'-TTCCAGCGGCAGATGAAGG-3'
Defensin NP1 like	5'-TGCTGTTCAAAGATTTACGCG-3'	5'-ACCTTGATAGCCGAATGCAGC-3'
Defensin NP3	5'-CTCCCTGCATACGCCAAAG-3'	5'-AACAGAGTCGGTAGATGCC-3'
Defensin $\alpha 5$	5'-AACTGTCTCTCTTCTGCCC-3'	5'-AACATCAGCATCGGTGGCC-3'
Defensin NP4	5'-GACACTCACTCTGCTCATCA-3'	5'-ATGACAATGGCTTCTTCTC-3'
Defensin $\beta 1$	5'-CTTGAGCGCAGAACAGATCA-3'	5'-AAACCACTGTCAACTCTGC-3'
β -Actin	5'-GACTTCGAGCAAGAGATGGC-3'	5'-AGGAAGGAAGGCTGGAAGAG-3'
G3PDH	5'-TCATGACCACAGTCCATGCC-3'	5'-CTCAGTGTAGCCAGGATGC-3'




Fig. 1. Numbers of genes over- or underexpressed in colon cancers. Numbers of genes (A) overexpressed or (B) underexpressed in colon cancers of F344 or ACI rats are indicated in Venn diagrams. These genes showed significant differences ($P < 0.05$, Mann-Whitney U -test) between colon cancer tissues and normal colon tissues of ≥ 3 -fold. The numbers in parentheses indicate the numbers of genes that also showed ≥ 2 -fold differences in ACI (a) and F344 (b), respectively.

repeated twice, all of which gave similar results, and representative data are shown.

Results

Gene expression profiles in colon cancers of two rat strains
Of 8749 genes or ESTs on the RG U34A array, 89 and 97 were overexpressed ≥ 3 -fold in colon cancers of F344 and ACI rats, respectively, and 109 and 183 were underexpressed by ≤ 3 -fold, as shown in the Venn diagrams (Figure 1A and B; GeneChip data are available at <http://www.ncc.go.jp/jp/nccri/divisions/02bioc/02bioc.html>). As illustrated in Figure 1(A), 27 were overexpressed ≥ 3 -fold in common in both F344 and ACI lesions. Although 62 genes were shown to be preferentially overexpressed in F344-derived colon cancers, 33 were also overexpressed ≥ 2 -fold, in both strains (Figure 1A). Similarly, 32 of 70 genes overexpressed ≥ 3 -fold in ACI rats were also overexpressed in the F344 strain by ≥ 2 -fold. Collectively, of 159 genes which showed ≥ 3 -fold expression in cancer tissues in either of the rat strains (Figure 1A), 92 (57.8%) showed ≥ 2 -fold expression in colon cancers in both strains. Similarly, 158 of 246 (64.2%) genes demonstrated ≤ 2 -fold expression in colon cancers in both strains (Figure 1B). We have recently reported that a considerable number of genes are differentially expressed in normal parts of colon epithelial cells between F344 and ACI rats after PhIP treatment (18) and the repertoire of differentially expressed genes may partly account for the different susceptibilities of the two rat strains. In contrast, differences in cancer tissues were relatively small compared with those in normal tissues. Permutation analysis was unable to detect apparent differences in the number of differentially expressed genes between cancer tissues of F344 and ACI rats, although significant differences were present in normal colon epithelium (data not shown). Hierarchical clustering analysis using the entire list of over- and underexpressed

genes in cancers could not elucidate any cluster(s) of genes specific for either strain (data not shown).

Genes overexpressed in colon cancers

As described above, 27 genes were overexpressed ≥ 3 -fold in common in both F344 and ACI rats (Figure 1A). Despite our efforts to elucidate meaningful signal pathways in those 27 genes using the bioinformatics software package GenMapp (<http://www.genmapp.org/>), none could be identified. This could be due, at least in part, to insufficient coverage of genes in signal pathway databases for rats. Manual classification, however, was able to elucidate some interesting tendencies. Genes involved in inflammation, such as those encoding interleukin 1 β , small inducible cytokine subfamily A20 precursor, and proteases, such as *matrilysin (Mmp7)* and *macrophage metalloelastase (Mme)* were highly overexpressed in cancer tissues (Table II). A cell cycle regulator, *cyclin D2*, and the cancer-related gene *retrotransposon virus-like 30s sequence (VL30)*, which is known to be overexpressed in rodent hepatocellular tumors and lymphomas (19,20), were also highly expressed. Interestingly, a subset of genes encoding defensin and defensin-like proteins, which belong to the small cationic antimicrobial cytotoxic peptides (21–23), were overexpressed ≥ 10 -fold. Differential expression of some of the representative genes was confirmed by semi-quantitative RT-PCR (Figure 2A).

Genes underexpressed in colon cancers

Forty-six genes were underexpressed ≤ 3 -fold in common in colon cancers of both the F344 and ACI strains (Figure 1B). Genes encoding metabolic enzymes, such as alanine aminotransferase, minoxidil sulfotransferase and carbonic anhydrase IV, and signal transduction molecules were among the list (Table III). A considerable number of transcripts related to the structural proteins, i.e. skeletal and smooth muscle-related proteins, matrix-composing proteins and mucin-like proteins, were underexpressed in colon cancers. Down-regulation of mucin genes in colon cancers may reflect the drastic decrease in or complete loss of goblet cells in cancer tissues. Representative results of RT-PCR analyses are depicted in Figure 2A.

Expression of oncogenes and tumor suppressor genes

Expression of tumor-related genes, including those considered to be involved in colon carcinogenesis, was also evaluated utilizing the Chip data. Signals for the *Apc*, *bcl2*, *c-jun*, *erbB3*, *VHL* and *WT1* genes were below detectable levels. The *p53* and *c-fos* genes were expressed at comparable levels in both colon cancers and normal parts of colon tissues (data not shown). Only the *c-myc* gene was expressed at a significantly higher level in cancer tissues than in normal counterparts in both rat strains, with 4.0- and 2.5-fold differences in F344 and ACI rats, respectively.

Comparison of gene expression profiles with human colon cancers

Some of the genes in the list have already been reported to be either over- or underexpressed in human colon cancers (24,25). Average fold changes between colon cancers and normal counterparts were calculated using combined data from both the F344 and ACI strains and genes with ≥ 5 -fold differences are listed in Table IV and compared with human cases, referring to the literature (24–31). The *defensin $\alpha 5$* and *defensin $\alpha 6$* genes were previously reported

Table II. Genes overexpressed in tumors of both F344 and ACI rats^a

Gene name	Average signal intensity				Fold change (T/N) ^b	
	F344		ACI		F344	ACI
	Normal	Tumor	Normal	Tumor		
HLA and immune function genes						
Anti-acetylcholine receptor antibody gene, rearranged Ig Gamma-2a chain, VDJC region	246.73	3738.53	200.00	3929.67	15.15	19.65
Cytokines, inflammatory mediators, antimicrobial						
(EST) A1639089/similar to mouse defensin NP1 (α 1)	1765.02	35820.01	200.00	55038.35	20.29	275.19
Defensin NP3 (α 3) gene	898.73	14754.13	919.32	12107.13	16.42	13.17
Interleukin 1- β mRNA	200.00	1225.78	200.00	1658.88	6.13	8.29
Small inducible cytokine subfamily A20	573.80	2328.28	582.04	3176.26	4.06	5.46
Mob-1	214.46	758.60	200.00	979.33	3.54	4.90
Detoxification enzymes						
Glutathione S-transferase M5 (Gst-M5)	334.82	2013.20	259.33	1366.90	6.01	5.27
Protease and protease inhibitors						
Matrilysin (Mmp-7) mRNA	200.00	5823.69	200.00	15258.13	29.12	76.29
Macrophage metalloelastase (Mme)	200.00	2047.38	200.00	1990.87	10.24	9.95
Maspin	677.18	1954.74	637.72	2957.50	2.89	4.64
Ion transporters, carrier proteins						
Cation transporter Oct1A	1180.79	6642.65	756.38	6553.23	5.63	8.66
Intracellular calcium-binding protein Mrp14	200.00	1004.26	200.00	2011.03	5.02	10.06
Signal transduction molecules, transcription factor						
Mash-2 mRNA expressed in neuronal precursor cells	200.00	2867.48	303.83	3381.59	14.34	11.13
Platelet phospholipase A2	6078.53	54470.52	7630.13	99549.62	8.96	13.05
Receptor-linked protein tyrosine phosphatase	281.53	2171.51	200.00	2747.78	7.71	13.74
Inhibitor of DNA binding 3 (Idb3)	1585.27	7556.29	1819.98	9419.78	4.77	5.18
Hypertension-regulated vascular factor-1 (Ruk)	1956.67	7039.99	961.72	4728.72	3.60	4.92
Cell cycle regulators						
Cyclin D2	200.00	1281.43	200.00	1218.13	6.41	6.09
Similar to cyclin D2 (Vin1)	5132.35	19215.31	3399.26	18358.46	3.74	5.40
Cancer-related genes (function unknown)						
VL30 element	1055.79	10942.00	1234.52	6470.70	10.36	5.24
c-Ha-ras protooncogene mechanism sequence	4157.40	32175.09	2926.38	26356.43	7.74	9.01
Structural proteins						
Type I keratin (Mhr a-1)	200.00	3584.60	200.00	1440.44	17.92	7.20
β -Tubulin T β 15	2176.01	8522.65	3252.25	11450.90	3.92	3.52
Serum protein						
α 2-Macroglobulin	903.14	5880.35	1023.80	6303.21	6.51	6.16
Function unknown						
(EST) AA859937	572.42	5572.50	251.35	5924.12	9.73	23.57
(EST) AA799396	955.18	4061.69	1094.52	5774.63	4.25	5.28

^aGenes with ≥ 3 -fold difference compared with those in normal counterpart tissues are listed.

^bFold changes were calculated by dividing the signal intensity of colon cancer tissue by that of normal colon tissue.

to be up-regulated in human colon cancers [SAGE data (25)]. In the present study, *defensin NP3* (α 3) and *defensin NP1* (α 1)-like molecule were revealed to be overexpressed, although they have not been reported to be overexpressed in human cases. The matrix proteases *Mmp-7* and *Mme* [DNA chip data (24)] and *Mash2*, *Mrp14* and *cyclin D2* [SAGE data (25)] were also reported to be highly expressed in human colon cancers. In the case of underexpressed genes, many of them were also reported to be down-regulated in human cancers, such as *mucin*, *guanylin*, *carbonic anhydrase IV* and several muscle- and structure-related genes (24,32).

Expression of defensin family genes in rat colon cancers

Defensin genes are composed of mainly two families, α and β , categorized by sequence similarities (23,33). Genes in the former group are expressed mainly in neutrophils and some in the intestine, while the latter are ubiquitously expressed. *defensin NP1* (α 1)-like molecule and *defensin NP3* (α 3) was

found to be highly expressed in colon cancers of both strains. *In situ* hybridization analysis revealed mRNAs of *defensin NP3* (α 3) and *defensin* α 5 to be expressed exclusively in epithelial cells of colon cancers and not expressed in matrix cells (Figure 3A). Normal epithelium did not show any positive signals. Overexpression of these genes in colon cancer tissues was confirmed by RT-PCR (Figure 2B). *defensin* α 5, which is an intestinal-type defensin, but is not on the Gene-Chip, was also expressed exclusively in colon cancers. No expression was observed for *defensin NP4* (α 4), *defensin* β 1 (Figure 2B) or *defensin* β -2 (data not shown) in either cancers or normal counterpart tissues.

Presence of Paneth cells in cancers and preneoplastic lesions of the colon

Since intestinal-type defensins are known to be produced in Paneth cells (23,34), we examined the expression of other marker proteins specific to the Paneth cell lineage. H&E and




Fig. 2. Semi-quantitative RT-PCR analysis. (A) Among genes over- or underexpressed in colon cancers, expression levels of representative examples were confirmed by semi-quantitative RT-PCR analysis. Each lane indicates the gene expression level of either tumor or normal counterpart tissue from individual animals. The upper four panels illustrate higher expression of *matrilysin*, *defensin NP3*, *Mash2* and *Oct1A*, respectively, in cancer tissues (T₁₋₃) compared with normal epithelium (N₁₋₃). In contrast, *carbonic anhydrase IV* and *phosphoglucosylase 1* were underexpressed in cancers. Expression of β -actin and *G3PDH* was analyzed as an internal control. The amounts of PCR products were quantified by NIH image software. The signal values were calculated by subtracting blank values, which are average signal intensities of three different points outside the signal bands. Fold differences were calculated by dividing the average of the value of colon cancer tissues (T) by that of normal colon tissues (N). N.D. indicates a sample with no PCR product visible to the naked eye. (B) Expression levels of several *defensin* genes were analyzed by RT-PCR. *Defensin NP1-like molecule*, *defensin NP3*, *defensin 5* and *defensin NP4* are α -*defensin* family genes and *defensin β 1* belongs to the β -*defensin* family gene. Quantification of the amounts of PCR products was carried out as above.

AB-PAS staining revealed the presence of Paneth granules in colon cancer cells and lysozyme expression was also observed in cells with Paneth granules (Figure 3B). Furthermore, Paneth cells were observed in adenomas and, to our surprise, even in preneoplastic lesions. When examined by H&E and AB-PAS

staining, three of eight colon cancers and two of three high grade dysplastic ACF observed at 18 or 25 weeks were demonstrated to contain Paneth cells within the lesion (Figure 4A). None of the non-dysplastic ACF demonstrated Paneth cell differentiation (Figure 4B).

Table III. Genes underexpressed in tumors of both F344 and ACI rats^a

Gene name	Average signal intensity				Fold change (T/N) ^b	
	F344		ACI		F344	ACI
	Normal	Tumor	Normal	Tumor		
Stress proteins and antioxidant						
Heat shock protein 27	8538.00	1967.31	11801.28	2648.38	4.34	4.46
Hsp70.2 mRNA for heat shock protein 70	766.00	200.00	3572.83	210.58	3.83	16.97
Metabolic enzymes						
Alanine aminotransferase mRNA	2078.57	200.00	1557.94	200.00	10.39	7.79
Minoxidil sulfotransferase	2170.13	208.88	1748.53	357.00	10.39	4.90
Carbonic anhydrase IV	2467.84	302.40	2651.28	220.07	8.16	12.05
Inducible carbonyl reductase	1676.98	234.19	1690.85	424.75	7.16	3.98
Skeletal muscle creatine kinase composite	1127.20	237.98	903.73	249.44	4.74	3.62
Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase	8830.96	2414.46	9434.23	939.58	3.66	10.04
Monoamine oxidase B	680.05	200.00	918.93	200.00	3.40	4.59
Lipoprotein lipase	2259.29	684.09	2316.56	225.35	3.30	10.28
Protease						
Endopeptidase-24.18 α subunit	3327.41	773.59	5676.14	570.71	4.30	9.95
Ion transporters, carrier proteins						
SC1 protein	45395.45	3784.08	24395.65	1981.58	12.00	12.31
Dihydropyridine-sensitive L-type Ca^{2+} channel α -2 subunit	1420.65	229.11	3067.40	200.00	6.20	15.34
Guanylin	26005.42	5019.71	34049.06	6235.18	5.18	5.46
Growth factors and hormones						
Insulin growth factor-binding protein	2446.05	240.24	3255.07	200.00	10.18	16.28
Ebnerin	31568.63	3536.31	5773.52	1388.94	8.93	4.16
Signal transduction molecules, transcription factors						
Neuron-specific protein Pep-19	3125.96	200.00	2721.96	200.00	15.63	13.61
Phospholipase C- β 1b	1714.75	244.15	2137.83	323.40	7.02	6.61
D-binding protein	1368.84	200.00	1038.96	200.00	6.84	5.19
Guanylate cyclase 1, soluble, α 3	2375.39	384.13	1670.49	519.78	6.18	3.21
Gap-43 gene	1666.24	271.56	982.00	293.22	6.14	3.35
Ssecks 322	6158.29	1093.83	3320.23	522.72	5.63	6.35
N-myc downstream regulated 2	2273.34	486.21	3961.73	710.56	4.68	5.58
Te10-like rho GTPase	2287.18	582.64	4295.60	511.18	3.93	8.40
BTE-binding protein	2136.52	625.70	3136.92	668.54	3.41	4.69
Structural proteins						
H36- α 7 integrin α chain	11056.70	501.93	4844.89	392.89	22.03	12.33
α -Crystallin B chain	4016.12	200.00	3133.37	383.01	20.08	8.18
α b-Crystallin-related protein	4322.27	375.25	3731.25	200.00	11.52	18.66
Mucin-like protein	85858.60	26168.84	85879.95	15703.47	3.28	5.47
Muscle-related proteins						
Skeletal muscle β -tropomyosin and fibroblast tropomyosin I	15036.62	578.13	8208.40	331.54	26.01	24.76
Myosin regulatory light chain isoform C	32928.30	1592.13	21440.35	576.02	20.68	37.22
γ -Enteric smooth muscle actin isoform	107504.58	5932.44	64435.47	1234.91	18.12	52.18
Calponin	22307.16	1283.39	14767.63	349.48	17.38	42.26
SM22 mRNA	25962.76	1742.56	9714.69	200.00	14.90	48.57
Alternatively spliced smooth muscle myosin heavy chain	21642.04	1629.01	13526.24	591.39	13.29	22.87
Vascular α -actin	28016.47	4213.15	28042.35	2126.16	6.65	13.19
Function unknown						
(EST) AA799832/similar to mouse phosphoglucomutase 5	17333.24	629.26	16572.28	200.00	27.55	82.86
(EST) AA799773/similar to mouse C3H filamin	4300.66	387.96	5571.79	558.87	11.09	9.97
(EST) AA800735/similar to archvillin	3155.42	366.63	3353.20	360.25	8.61	9.31
(EST) AA799580	2256.37	338.94	1619.85	420.47	6.66	3.85
(EST) AA799734	1290.58	200.00	950.38	200.00	6.45	4.75
(EST) AA892888	5611.57	949.04	3961.43	200.00	5.91	19.81
zymogen granule protein (Zg-16p)	14971.90	2743.63	25128.90	1816.38	5.46	13.83
(EST) AA893743/similar to human hox B2	1017.45	200.00	952.02	200.00	5.09	4.76
(EST) A1639501/similar to human brain cell membrane protein 1	4324.68	871.69	4080.30	1027.55	4.96	3.97

^aGene with ≥ 3 -fold difference compared with those in normal counterpart tissues are listed.

^bFold changes were calculated by dividing the signal intensity of normal colon tissues by that of colon cancer tissues.

Discussion

With the present comprehensive gene expression analysis, conducted using PhIP-induced rat colon cancers in two rat strains, PhIP-induced colon cancers were found to possess

somewhat common gene expression profiles in both F344 and ACI rats, despite the significant differences in gene expression between their normal colon epithelium (18). Furthermore, a subset of genes known to be overexpressed in

Table IV. Comparison of overexpressed and underexpressed genes in tumors of rat and human

Gene name	Rat Fold	Human		
		DNA chip ^a	SAGE ^b	Other data
Overexpressed				
Defensin NP1 ($\alpha 1$)-like protein	53.30	Unchanged		
Matrilysin (Mmp-7) mRNA (EST) AA859937	41.89 14.37	8.00 c		Overexpressed (26,27)
Defensin NP3 ($\alpha 3$) gene	13.47	Unchanged		
Platelet phospholipase A2	12.02	Unchanged		Overexpressed (28)
Type I keratin (Mhr a-1)	9.86	c		
Anti-acetylcholine receptor antibody gene	9.63	c		
Mash-2 mRNA expressed in neuronal precursor cells	9.62	c	9/0	
c-Ha-ras protooncogene mechanism sequence	8.90	c		
Intracellular calcium-binding protein Mrp14	8.18	Unchanged	11/0	
Receptor-linked protein tyrosine phosphatase	8.06	c		
Macrophage metalloelastase (Mme)	7.45	5.10		
Cation transporter Oct1A	7.43	c		
VL30 element	6.75	c		
Interleukin 1- β mRNA	6.05	Unchanged		
Cyclin D2	5.60	Unchanged	8/0	Overexpressed (29)
$\alpha 2$ -Macroglobulin	5.55	c		Overexpressed (30)
Under-expressed				
(EST)AA799832	40.36	2.7		
H36- $\alpha 7$ integrin α chain	15.58	2.8		
Neuron-specific protein Pep-19 mRNA, complete cds	13.61	2.1		
Sc1 protein	12.18	4.5		Underexpressed (31)
Zg-16p	11.35	c		
α b-crystallin-related protein	11.34	c		
Dihydropyridine-sensitive L-type calcium channel	10.42	Unchanged		
α -Crystallin B chain	10.19	4.3		
(EST)AF119148/Musmus C3H filamin	9.56	5.8		
Alanine aminotransferase mRNA	9.35	c		
Insulin growth factor-binding protein	9.28	1.6		
(EST)AA892888	7.77	c		
Carbonic anhydrase IV	7.68	2		
(EST) AA800735/similar to mouse Supravillin	7.16	c		
Guanylin	6.04	20	55/0	
Phospholipase C- $\beta 1b$	5.78	c		
Ssecks 322	5.68	c		
D-binding protein	5.05	c	8/0	

The values indicate tag counts of normal tissues/tumor tissues.

^aData from Notterman *et al.* (24). Values indicate fold difference (normal/tumor).

^bData from Buchhaults *et al.* (25) and on-line SAGE database to which they submitted their results.

^cThere is no information in Notterman *et al.* (24) about these genes.

human colon cancers was highly expressed in colon cancers of both rat strains. In addition, there are substantial similarities in a list of underexpressed genes between human (24) and rat tumors (present study). The histological features of the rat cancers also showed a high similarity with human cases, as described previously (10,11,13,14). Taking all the data together, the PhIP-induced colon carcinogenesis model in rats thus appears an appropriate and relevant system for investigation of human colon carcinogenesis.

High expression of *cyclin D2* and *c-myc* may result from activation of the Wnt/ β -catenin signaling pathway as a consequence of β -catenin accumulation, this being a common feature in rat and human tumors (2,13,35). An mRNA species for a mucin-like protein, homologous to mouse mucin 2, was here shown to be underexpressed in cancer tissues. Mucins are known to be abnormally expressed in neoplastic lesions of the colon of humans (36). Moreover, since *mucin 2*^{-/-} mice demonstrated reduced numbers of goblet cells and spontaneously developed adenomas in the small intestine (37), down-regulation of the mucin-like protein mRNA may play an important role in PhIP colon carcinogenesis in rats.

Some of the genes found in the present study, including those encoding helix-loop-helix protein MASH2, organic cation transporter (OCT1A4), calcium-binding protein MRP14 and regulator of ubiquitous kinase (RUK), have not been reported so far to be differentially expressed in human colon cancers. Some of them are intriguing with regard to their biological functions, although there are few reports suggesting their involvement in human colon carcinogenesis. Considering the size (small), the non-invasive nature of rat lesions and the rare occurrence of *p53* or *K-ras* mutations in PhIP-induced colon cancers (38,39), differential expression of these genes in cancer tissues may suggest that their alteration occurs at an early stage of human colon carcinogenesis. Alternatively, of course, this could simply be a rodent-specific phenomenon. Further analysis is warranted in the future to clarify this point.

Snyderwine *et al.* recently reported gene expression profiles in PhIP-induced mammary gland tumors (40). Expression of a few genes overlapped between mammary gland (40) and colon tumors (present study) induced by PhIP, except for the *tubulin $\beta 15$* gene. In PhIP-induced rat mammary cancer, deregulation of cyclin D1/Cdk4 and phospho-Rb was postulated to play a




Fig. 3. Histological analysis of colon cancer tissues. (A) Frozen tissue sections were subjected to AB-PAS staining (a) and *in situ* hybridization with a *defensin NP3* (b) or *defensin 5* probe (c). Arrowheads in (b) and (c) indicate cells with *defensin NP3* and *defensin 5* transcripts, respectively. (B) Serial sections of paraffin embedded colon cancer tissues were subjected to H&E staining (a), AB-PAS staining (b) and immunostaining with an anti-lysozyme IgG antibody (c). As arrowheads indicate, Paneth cells can be recognized by the presence of typical pink granules (Paneth granules) by H&E staining. Paneth granules are also clearly visualized by AB-PAS staining (b) and by immunostaining for lysozyme protein (c).

central role (41). The results indicate that the molecular basis underlying PhIP carcinogenesis could differ from organ to organ, although cell proliferation may be accelerated by PhIP in both cases. In fact, β -catenin mutations are frequently observed in rat colon cancers (11–13), but only rarely in mammary tumors (42). Moreover, the mutation spectra found in PhIP-induced tumors also differ with the organ (43).

It is of great interest to note that Paneth cells were observed in colon cancers and even in much earlier lesions, dysplastic ACF. Paneth cells exist mainly in the small intestine and sometimes in colonic tumors, but are rarely found in normal colon epithelium (44,45). Yamada *et al.* have recently reported the presence of Paneth cells in crypts which accumulated β -catenin (BCAC) induced by an alkylating agent, azoxymethane (46,47). Based on their observations and a previous report by Wilson *et al.* (48), Yamada and Mori (49) suggested a dysdifferentiating potential of BCAC and that Paneth cell differentiation could promote intestinal carcinogenesis. Taking the results together, the appearance of Paneth cells in colon cancers does not appear to be carcinogen-specific, but could be a common phenomenon in the development of colon cancers. Although the molecular mechanisms underlying the induction of Paneth cells in colon cancers remain to be clarified, activation of the Wnt/Apc/ β -catenin signaling pathway could be one

causative event. Inhibition of β -catenin/TCF signaling in colon cancer cell lines indeed results in G₁ arrest or induction of markers which are characteristic of differentiated colon epithelial cells, as described previously (50). Mice deficient for the TCF4 transcription factor completely lack proliferating cells in the fetal small intestinal epithelium (51). The Wnt/APC/ β -catenin signaling pathway thus could be essential for maintenance of the differentiated or undifferentiated status of intestinal epithelial cells. Activation of the Wnt/APC/ β -catenin pathway may therefore affect the differentiation process and induce dysdifferentiation of colon epithelial cells as a consequence. Activation of this pathway is commonly observed in both PhIP- (10–15) and azoxymethane-induced (35,52,53) colon cancers and also in preneoplastic lesions (15). Gene expression analysis of teratomas, derived from embryonic stem cells with null APC, showed up-regulation of *defensin* α genes compared with teratomas derived from embryonic stem cells with wild-type APC (54). Paneth cells were also observed in APC-deficient teratoma tissues (54). Again, it is highly plausible that activation of the Wnt/APC/ β -catenin signaling pathway is a genetic causation of Paneth cell differentiation in colon cancer tissues. Although the biological consequences of Paneth cell differentiation (or metaplasia) for colon carcinogenesis remain to be clarified, it is




Fig. 4. Histological analysis of ACF. Serial sections of paraffin embedded high grade dysplastic (A) and non-dysplastic ACF (B) observed at experimental week 18. AB-PAS-positive Paneth granules are clearly evident in the high grade dysplastic ACF, but not in the non-dysplastic lesion. Another high grade dysplastic ACF collected at week 25 also gave similar results (data not shown). (a) H&E staining; (b) AB-PAS staining.

possible that the appearance of Paneth cells reflects aberrant differentiation of colonic stem cells. Whatever the case, defensin could be utilized as a potential serological marker for early detection of colon cancers because of its nature as a secreted molecule.

Acknowledgements

This work was supported in part by a Grant-in-Aid for the Second Term of the Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan, and by a Grant-in-Aid for Scientific Research on Priority Areas of Cancer from the Ministry of Education, Science, Sport, Culture and Technology of Japan. K.F. was the recipient of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research in Japan while this work was being conducted.

References

- Chung, D.C. (2000) The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. *Gastroenterology*, **119**, 854–865.
- Kinzler, K.W. and Vogelstein, B. (2002) Colorectal tumors. In Kinzler K.W. and Vogelstein B. (eds), *The Genetic Basis of Human Cancer*. McGraw-Hill, New York, NY, pp. 583–612.
- Felton, J.S., Knize, M.G., Shen, N.H., Lewis, P.R., Andresen, B.D., Happe, J. and Hatch, F.T. (1986) The isolation and identification of a new mutagen from fried ground beef: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). *Carcinogenesis*, **7**, 1081–1086.
- Wakabayashi, K., Nagao, M., Esumi, H. and Sugimura, T. (1992) Food-derived mutagens and carcinogens. *Cancer Res.*, **52**, 2092s–2098s.
- Takahashi, S., Ogawa, K., Ohshima, H., Esumi, H., Ito, N. and Sugimura, T. (1991) Induction of aberrant crypt foci in the large intestine of F344 rats by oral administration of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Jpn. J. Cancer Res.*, **82**, 135–137.
- Ochiai, M., Nakagama, H., Watanabe, M., Ishiguro, Y., Sugimura, T. and Nagao, M. (1996) Efficient method for rapid induction of aberrant crypt foci in rats with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Jpn. J. Cancer Res.*, **87**, 1029–1033.
- Bird, R.P. (1987) Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. *Cancer Lett.*, **37**, 147–151.
- McLellan, E.A. and Bird, R.P. (1988) Aberrant crypts: potential preneoplastic lesions in the murine colon. *Cancer Res.*, **48**, 6187–6192.
- Ito, N., Hasegawa, R., Sano, M., Tamano, S., Esumi, H., Takayama, S. and Sugimura, T. (1991) A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). *Carcinogenesis*, **12**, 1503–1506.
- Kakiuchi, H., Watanabe, M., Ushijima, T., Toyota, M., Imai, K., Weisburger, J.H., Sugimura, T. and Nagao, M. (1995) Specific 5'-GGGA-3' > 5'-GGA-3' mutation of the Apc gene in rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Proc. Natl Acad. Sci. USA*, **92**, 910–914.

11. Dashwood, R.H., Suzui, M., Nakagama, H., Sugimura, T. and Nagao, M. (1998) High frequency of β -catenin (*ctnnb1*) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat. *Cancer Res.*, **58**, 1127-1129.
12. Tsukamoto, T., Tanaka, H., Fukami, H., Inoue, M., Takahashi, M., Wakabayashi, K. and Tatematsu, M. (2000) More frequent beta-catenin gene mutations in adenomas than in aberrant crypt foci or adenocarcinomas in the large intestines of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-treated rats. *Jpn. J. Cancer Res.*, **91**, 792-796.
13. Ubagai, T., Ochiai, M., Kawamori, T., Imai, H., Sugimura, T., Nagao, M. and Nakagama, H. (2002) Efficient induction of rat large intestinal tumors with a new spectrum of mutations by intermittent administration of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in combination with a high fat diet. *Carcinogenesis*, **23**, 197-200.
14. Nakagama, H., Ochiai, M., Ubagai, T., Tajima, R., Fujiwara, K., Sugimura, T. and Nagao, M. (2002) A rat colon cancer model induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, PhIP. *Mutat. Res.*, **506/507**, 137-144.
15. Ochiai, M., Ushigome, M., Fujiwara, K., Ubagai, T., Kawamori, T., Sugimura, T., Nagao, M. and Nakagama, H. (2003) Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Am. J. Pathol.*, **163**, 1607-1614.
16. Hoshino, M., Sone, M., Fukata, M., Kuroda, S., Kaibuchi, K., Nabeshima, Y. and Hama, C. (1999) Identification of the *stef* gene that encodes a novel guanine nucleotide exchange factor specific for Rac1. *J. Biol. Chem.*, **274**, 17837-17844.
17. Yoshida, S., Ohbo, K., Takakura, A., Takebayashi, H., Okada, T., Abe, K. and Nabeshima, Y. (2001) Sgn1, a basic helix-loop-helix transcription factor delineates the salivary gland duct cell lineage in mice. *Dev. Biol.*, **240**, 517-530.
18. Fujiwara, K., Ochiai, M., Ubagai, T., Ohki, M., Ohta, T., Nagao, M., Sugimura, T. and Nakagama, H. (2003) Differential gene expression profiles in colon epithelium of two rat strains with distinct susceptibility to colon carcinogenesis after exposure to PhIP in combination with dietary high fat. *Cancer Sci.*, **94**, 672-678.
19. Dragani, T.A., Manenti, G., Della Porta, G., Gattoni-Celli, S. and Weinstein, I.B. (1986) Expression of retroviral sequences and oncogenes in murine hepatocellular tumors. *Cancer Res.*, **46**, 1915-1919.
20. van der Houven van Oordt, C.W., Schouten, T.G., van der Eb, A.J. and Breuer, M.L. (1999) Differentially expressed transcripts in X-ray-induced lymphomas identified by dioxigenin-labeled differential display. *Mol. Carcinog.*, **24**, 29-35.
21. Ouellette, A.J., Hsieh, M.M., Nosek, M.T., Cano-Gauci, D.F., Huttner, K.M., Buick, R.N. and Selsted, M.E. (1994) Mouse Paneth cell defensins: primary structures and antibacterial activities of numerous cryptdin isoforms. *Infect. Immun.*, **62**, 5040-5047.
22. Yount, N.Y., Wang, M.S., Yuan, J., Banaice, N., Ouellette, A.J. and Selsted, M.E. (1995) Rat neutrophil defensins. Precursor structures and expression during neutrophilic myelopoiesis. *J. Immunol.*, **155**, 4476-4484.
23. Ouellette, A.J. (1997) Paneth cells and innate immunity in the crypt microenvironment. *Gastroenterology*, **113**, 1779-1784.
24. Notterman, D.A., Alon, U., Sierk, A.J. and Levine, A.J. (2001) Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma and normal tissue examined by oligonucleotide arrays. *Cancer Res.*, **61**, 3124-3130.
25. Buckhaults, P., Rago, C., St Croix, B., Romans, K.E., Saha, S., Zhang, L., Vogelstein, B. and Kinzler, K.W. (2001) Secreted and cell surface genes expressed in benign and malignant colorectal tumors. *Cancer Res.*, **61**, 6996-7001.
26. McDonnell, S., Navre, M., Coffey, R.J., Jr and Matrisian, L.M. (1991) Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. *Mol. Carcinog.*, **4**, 527-533.
27. Yoshimoto, M., Itoh, F., Yamamoto, H., Hinoda, Y., Imai, K. and Yachi, A. (1993) Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. *Int. J. Cancer*, **54**, 614-618.
28. Kennedy, B.P., Soravia, C., Moffat, J., Xia, L., Hiruki, T., Collins, S., Gallinger, S. and Bapat, B. (1998) Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. *Cancer Res.*, **58**, 500-503.
29. Bartkova, J., Thullberg, M., Slezak, P., Jaramillo, E., Rubio, C., Thomassen, L.H. and Bartek, J. (2001) Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon. *Gastroenterology*, **120**, 1680-1688.
30. Cooper, E.H., Tumer, R., Geekie, A., Neville, A.M., Goligher, J.C., Graham, N.G., Giles, G.R., Hall, R. and Macadam, W.A. (1976) Alpha-globulins in the surveillance of colorectal cancer. *Biomedicine*, **24**, 171-178.
31. Claeskens, A., Ongenaes, N., Neefs, J.M., Cheyns, P., Kaijen, P., Cools, M. and Kutoh, E. (2000) Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. *Br. J. Cancer*, **82**, 1123-1130.
32. Birkenkamp-Demtroder, K., Christensen, L.L., Olesen, S.H., Frederiksen, C.M., Laiho, P., Aaltonen, L.A., Laurberg, S., Sorensen, F.B., Hagemann, R. and ORntoft, T.F. (2002) Gene expression in colorectal cancer. *Cancer Res.*, **62**, 4352-4363.
33. Ganz, T. (1999) Defensins and host defense. *Science*, **286**, 420-421.
34. Mallow, E.B., Harris, A., Salzman, N., Russell, J.P., DeBerardinis, R.J., Ruchelli, E. and Bevins, C.L. (1996) Human enteric defensins. Gene structure and developmental expression. *J. Biol. Chem.*, **271**, 4038-4045.
35. Takahashi, M., Fukuda, K., Sugimura, T. and Wakabayashi, K. (1998) β -catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. *Cancer Res.*, **58**, 42-46.
36. Ho, S.B., Niehans, G.A., Lyftogt, C., Yan, P.S., Cherwitz, D.L., Gum, E.T., Dahiya, R. and Kim, Y.S. (1993) Heterogeneity of mucin gene expression in normal and neoplastic tissues. *Cancer Res.*, **53**, 641-651.
37. Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., Kucherlapati, R., Lipkin, M., Yang, K. and Augenlicht, L. (2002) Colorectal cancer in mice genetically deficient in the mucin Muc2. *Science*, **295**, 1726-1729.
38. Ushijima, T., Kakiuchi, H., Makino, H., Hasegawa, R., Ishizaka, Y., Hirai, H., Yazaki, Y., Ito, N., Sugimura, T. and Nagao, M. (1994) Infrequent mutation of Ha-ras and p53 in rat mammary carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Mol. Carcinog.*, **10**, 38-44.
39. Makino, H., Ushijima, T., Kakiuchi, H., Onda, M., Ito, N., Sugimura, T. and Nagao, M. (1994) Absence of p53 mutations in rat colon tumors induced by 2-amino-6-methylidiprido[1,2-a:3',2'-d]imidazole, 2-amino-3-methylimidazo[4,5-f]quinoline, or 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Jpn. J. Cancer Res.*, **85**, 510-514.
40. Shan, L., He, M., Yu, M., Qiu, C., Lee, N.H., Liu, E.T. and Snyderwine, E.G. (2002) cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[*a*]anthracene. *Carcinogenesis*, **23**, 1561-1568.
41. Qiu, C., Shan, L., Yu, M. and Snyderwine, E.G. (2003) Deregulation of the cyclin D1/Cdk4 retinoblastoma pathway in rat mammary gland carcinomas induced by the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Cancer Res.*, **63**, 5674-5678.
42. Yu, M., Ryu, D.Y. and Snyderwine, E.G. (2000) Genomic imbalance in rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Mol. Carcinog.*, **27**, 76-83.
43. Okochi, E., Watanabe, N., Shimada, Y., Takahashi, S., Wakazono, K., Shirai, T., Sugimura, T., Nagao, M. and Ushijima, T. (1999) Preferential induction of guanine deletion at 5'-GGGA-3' in rat mammary glands by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Carcinogenesis*, **20**, 1933-1938.
44. Shousha, S. (1979) Paneth cell-rich papillary adenocarcinoma and a mucoid adenocarcinoma occurring synchronously in colon: a light and electron microscopic study. *Histopathology*, **3**, 489-501.
45. Pai, M.R., Coimbatore, R.V. and Naik, R. (1998) Paneth cell metaplasia in colonic adenocarcinomas. *Indian J. Cancer*, **35**, 38-41.
46. Yamada, Y., Yoshimi, N., Hirose, Y., Matsunaga, K., Katayama, M., Sakata, K., Shimizu, M., Kuno, T. and Mori, H. (2001) Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. *Cancer Res.*, **61**, 1874-1878.
47. Hirose, Y., Kuno, T., Yamada, Y., Sakata, K., Katayama, M., Yoshida, K., Qiao, Z., Hata, K., Yoshimi, N. and Mori, H. (2003) Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. *Carcinogenesis*, **24**, 107-111.
48. Wilson, C.L., Ouellette, A.J., Satchell, D.P., Ayabe, T., Lopez-Boado, Y.S., Stratman, J.L., Hultgren, S.J., Matrisian, L.M. and Parks, W.C. (1999) Regulation of intestinal α -defensin activation by the metalloproteinase matrilysin in innate host defense. *Science*, **286**, 113-117.
49. Yamada, Y. and Mori, H. (2003) Pre-cancerous lesions for colorectal cancers in rodents: a new concept. *Carcinogenesis*, **24**, 1015-1019.

50. van de Wetering, M., Sancho, E., Verweij, C. *et al.* (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. *Cell*, **111**, 241–250.
51. Korinek, V., Barker, N., Moerer, P., van Donselaar, E., Huls, G., Peters, P.J. and Clevers, H. (1998) Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. *Nature Genet.*, **19**, 379–383.
52. Sheng, H., Shao, J., Williams, C.S., Pereira, M.A., Taketo, M.M., Oshima, M., Reynolds, A.B., Washington, M.K., DuBois, R.N. and Beauchamp, R.D. (1998) Nuclear translocation of β -catenin in hereditary and carcinogen-induced intestinal adenomas. *Carcinogenesis*, **19**, 543–549.
53. Takahashi, M., Nakatsugi, S., Sugimura, T. and Wakabayashi, K. (2000) Frequent mutations of the β -catenin gene in mouse colon tumors induced by azoxymethane. *Carcinogenesis*, **21**, 1117–1120.
54. Kielman, M.F., Rindapaa, M., Gaspar, C., van Poppel, N., Breukel, C., van Leeuwen, S., Taketo, M.M., Roberts, S., Smits, R. and Fodde, R. (2002) Apc modulates embryonic stem-cell differentiation by controlling the dosage of β -catenin signaling. *Nature Genet.*, **32**, 594–605.

*Received October 24, 2003; revised March 11, 2004;
accepted March 22, 2004*

Comprehensive expression analysis of a rat depression model

N Nakatani¹
 H Aburatani^{1,2}
 K Nishimura³
 J Semba^{1,4}
 T Yoshikawa¹

¹Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Wako, Saitama, Japan; ²Department of Cancer Systems Biology, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan; ³Department of Information Systems, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan; ⁴The University of the Air, Chiba, Japan

Correspondence:

Dr T Yoshikawa, Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
 Tel: +81 48 467 5968
 Fax: +81 48 467 7462
 E-mail: takeo@brain.riken.go.jp

ABSTRACT

Herein we report on a large-scale analysis of gene expression in the 'learned helplessness' (LH) rat model of human depression, using DNA microarrays. We compared gene expression in the frontal cortex (FC) and hippocampus (HPC) of untreated controls, and LH rats treated with saline (LH-S), imipramine or fluoxetine. A total of 34 and 48 transcripts were differentially expressed in the FC and HPC, respectively, between control and LH-S groups. Unexpectedly, only genes for NADH dehydrogenase and zinc transporter were altered in both the FC and HPC, suggesting limited overlap in the molecular processes from specific areas of the brain. Principal component analysis revealed that sets of upregulated metabolic enzyme genes in the FC and downregulated genes for signal transduction in the HPC can distinguish clearly between depressed and control animals, as well as explain the responsiveness to antidepressants. This comprehensive data could help to unravel the complex genetic predispositions involved in human depression. *The Pharmacogenomics Journal* (2004) 4, 114–126. doi:10.1038/sj.tpj.6500234

Keywords: learned helplessness; DNA microarray; frontal cortex; hippocampus; antidepressant

INTRODUCTION

Depression is a complex psychiatric disease with specific symptoms that include depressed mood, loss of interest, diminished appetite, sleep disturbances and psychomotor retardation. Depression is common, with lifetime prevalence estimated to be up to 20%,¹ and the condition exacts high personal and social costs on sufferers. The illness is also a major cause of suicide. Epidemiological studies suggest a genetic component to affective disorder,^{1,2} and efforts to identify susceptibility genes by linkage and other genetic analyses are being conducted.³ However, the precise etiologies remain elusive, as does the development of new therapies against depression, particularly for cases that are refractory to conventional therapy. In the case of complex trait diseases, isolating genetic mechanisms using human disease material is often difficult because of sample heterogeneity and other confounding factors. Analysis of suitable animal models under strictly controlled conditions would therefore be beneficial.

To investigate the molecular basis of depression, we have applied DNA microarray technology to analyze gene expressions in learned helplessness (LH) rats, an animal model of depression. After pretreatment with repeated inescapable shocks, animals with LH display decreased ability to escape adverse situations. This behavioral model was originally described in dogs,⁴ and later analogous behavior was induced in rats.⁵ LH animals display behavioral phenotypes resembling human depressive symptoms, and LH can be ameliorated

Received: 20 May 2003
 Revised: 03 November 2003
 Accepted: 10 December 2003

using antidepressant drugs.^{6,7} LH therefore fulfills the parameters of construct validity, face validity and predictive validity,⁸ confirming the suitability of the model for studying the neurobiology of depressive illness and the actions of antidepressants.^{9–11} It is also important to note that the 'depressive state' in LH animals lasts for over 3 weeks,¹² making this model particularly useful for studying the chronic changes in brain physiology that accompany depression. We examined the frontal cortex (FC) and hippocampus (HPC) of LH rats, because positron emission tomography scanning and functional magnetic resonance imaging studies have recently indicated a potential abnormality in the frontal cortex of both familial bipolar and unipolar depressives.¹³ In addition, recent evidence has suggested that neurogenesis in the HPC may be disturbed in depressive patients.^{14–16}

In this study, we have analyzed brain transcripts altered during LH and followed their responsiveness to a classical tricyclic antidepressant (TCA), imipramine, and a new generation selective serotonin reuptake inhibitor (SSRI), fluoxetine. In addition, we performed principal component analysis (PCA) to extract essential gene sets from complex expression data sets that can best explain the different pathophysiological conditions. This was achieved by considering genes as variables in PCA. When genes are variables, the analysis creates a set of principal gene components indicating the features of genes that best explain the experimental responses. Using these comprehensive pharmacological-behavioral genetic approaches, we have attempted to generate data that would eventually allow for the formulation of hypotheses to help understand the molecular and genetic pathophysiology of depression. This in turn could lead to the development of novel antidepressants with greater efficacy.

RESULTS AND DISCUSSION

Effectiveness of Antidepressants in Learned Helplessness

The LH model is difficult to generate, requiring meticulous refinement of multiple experimental parameters. In our experimental setting, after inescapable shock pretreatment, animals were subjected to 15 avoidance trials at 30 s intervals. In each trial, a current was applied via the floor grid during the first 3 s. If an animal moved to a neighboring compartment within this period (escape response), the shock was terminated. Failures in escape response were counted as a measure of LH. We defined animals as being in a state of LH when escape failures were demonstrated in more than half of the trials in the session. Using this system, we reproducibly induced LH in rats with a success rate of ~40%. LH rats were subsequently treated with repeated injections of saline (LH-S), fluoxetine (LH-F) or imipramine (LH-I), then re-evaluated for escape responses in the test session. Figure 1 shows a schematic of these procedures. During the escapable shock of the test session, all animals in the LH-S group ($n=10$) showed more than eight escape failures, and the mean failure was significantly higher than that of control rats (those that were not given inescapable




Figure 1 Schematic representation of behavioral procedures. (a) To induce the LH state, animals were given inescapable shock (Δ) on day 1. On day 2, they received escapable shock (\blacktriangle), and were selected as 'LH rats' if they showed greater than 50% failure in escape responses. LH animals were then administered saline (LH-S) or antidepressants (LH-F, LH-I) for 4 consecutive days. These animals received escapable shock (\blacktriangle) again on day 5 to determine whether they were still in the LH state. (b) Control rats were not given inescapable shock on day 1, but treated in the same way thereafter as the LH rats.




Figure 2 Mean number of escape failures (\pm SE) during the 15 avoidance trials. Controls ($n=15$) were not given inescapable shocks. Rats exposed to prior inescapable shocks were treated with saline (LH-S) ($n=10$), fluoxetine (LH-F) ($n=7$) or imipramine (LH-I) ($n=9$) once a day for consecutive days (days 2–5). Escape failure refers to the failure of animals to move into the safe compartment during electric footshock (0.5 mA, 3 s duration). The mean numbers of escape failures among groups were evaluated by ANOVA, $F(3,37) = 23.69$. $*P < 0.01$ and $**P < 0.001$ by *post hoc* Tukey–Kramer test.

shock, $n=15$) (Figure 2). Antidepressant administration significantly reduced the number of escape failures for both LH-F ($P < 0.05$) and LH-I ($P < 0.01$). Imipramine recovered all

rats from the LH state ($n=9$), and fluoxetine reinstated five out of seven. These results confirm the persistency of LH in our animals and the effectiveness of antidepressants in this model.^{5,17-20} Fluoxetine produced a weaker response compared to imipramine in alleviating the LH phenotype (Figure 2). We also tested larger doses of each drug, 10 mg/kg i.p. of fluoxetine and 50 mg/kg i.p. of imipramine, but did not observe any significant change in the number of escape failures (10 mg/kg of fluoxetine, 5.0 ± 1.0 ($n=3$); 50 mg/kg of imipramine, 2.0 ± 1.3 ($n=3$)) between the two doses. In addition, Anthony *et al*²¹ showed that 5 mg/kg of fluoxetine, the same dose as used in the present study, was enough to elicit monoaminergic perturbation such as a reduced 5-hydroxytryptamine receptor 1B expression in the dorsal raphe of rats. Bristow *et al*²² also demonstrated the validity and efficacy of 5 mg/kg of fluoxetine in ameliorating depressive behavior in rats. We attempted to minimize the nonspecific effects of the drugs by using the lowest possible dose that maintained antidepressive efficacy.

The present results may reflect the different clinical potencies of the individual agents. TCAs such as imipramine inhibit the reuptake of both serotonin and norepinephrine at nerve terminals by acting on monoamine transporters. In contrast, SSRIs including fluoxetine specifically block the reuptake of serotonin.² These differences in pharmacological profiles underlie the distinct antidepressive competences exerted by TCA and SSRI. Although human patients require over 2 weeks of medication before antidepressive effects are observed, we administered the drugs for 4 days in our rodent experiments, in keeping with the protocols of Geoffroy *et al*⁶ (5-day treatment) and Tordera *et al*²³ (4-day treatment), and could replicate distinct behavioral responses to therapy.

We also measured weight gain during the 5 days of experiments. Weight increase in the LH-S group was significantly lower than that in controls (LH-S, 18.8 ± 4.4 g; control, 31.7 ± 2.2 g; $P < 0.05$).

General Profiles of Gene Expressions Associated with LH and Antidepressant Treatments

We selected six animals each from the control (rats showing no escape failure in the escapable shock session) and LH-S groups, and five each from the LH-F and LH-I groups (these showed ≤ 7 failures in the 15 trials), to perform microarray analyses. Patterns of gene expression in the two brain regions from the four rat groups were examined using the Affymetrix GeneChip U34A, which represents 8799 probe sets and codes over 8000 transcripts including known genes (>5000) and expressed sequence tags (ESTs). Transcript expression from extracted RNA displayed good linearity in both FC and HPC samples (Figure 3). Our stringent criteria identified 34 and 48 transcripts as differentially expressed between control ($n=6$) and LH-S ($n=6$) groups in the FC and HPC, respectively (henceforth referred to as 'LH-associated transcripts') (Figures 3a and b). However, none of these transcripts survived after the Benjamin and Hochberg False Discovery Rate analysis. This observation may confirm the statements of Mirnics *et al*²⁴ that true gene-expression changes in psychiatric traits are small and




Figure 3 Scatter plot of log-intensity values for the over 8000 genes assayed with the RG-U34A chip in the frontal cortex (a) and hippocampus (b). Each point represents the log value from an average of six control or six LH-S animals.

psychiatric diseases may result from cumulative subtle changes.

Among LH-associated transcripts, five transcripts and one gene showed significant recovery to control levels from the LH state under both imipramine ($n=5$) and fluoxetine ($n=5$) administration in the FC and HPC, respectively (white portions in Figures 4a and b). Transcripts in the pink and yellow areas of Figure 4 represented expression levels that returned to normal after administration of imipramine and fluoxetine, respectively. Interestingly, no LH-associated transcripts demonstrated significant deviation from control levels after drug treatment. That is, none of the LH-associated genes were further decreased or excessively